ArticleFrontiers in immunology2022

A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.

He Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.